Evidence map›Paper›PMID 29862427›Full record

ArticleEuropean journal of clinical pharmacology2018

Tamoxifen and the risk of Parkinsonism: a case/non-case study.

François Montastruc, Farzin Khosrow-Khavar, Sibylle de Germay, Christel Renoux, Vanessa Rousseau, Geneviève Durrieu, Marion Montastruc, Olivier Rascol, Agnès Sommet, Maryse Lapeyre-Mestre and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Tamoxifen administration and the risk of Parkinsonism.European journal of clinical pharmacology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

François MontastrucLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Farzin Khosrow-KhavarCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada.
Sibylle de GermayLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Christel RenouxCentre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada.
Vanessa RousseauService de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Geneviève DurrieuService de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Marion MontastrucInstitut Universitaire du Cancer Toulouse-Oncopôle, 1 avenue Irène-Joliot-Curie, 31059, Toulouse, France.
Olivier RascolLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Agnès SommetLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Maryse Lapeyre-MestreLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Justine BeneventLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France.
Jean-Louis MontastrucLaboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université de Toulouse, 37 allées Jules-Guesde, 31000, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThree studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure.

objectivesTo explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase® between 1979 and 2018.

methodsAmong women ≥ 55 years, we measured the risk of reporting "Parkinsonism" compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors.

resultsDuring the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71-0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33-0.46).

conclusionThis study did not find evidence for Parkinsonism associated with tamoxifen.

Indexed as

Adverse Drug Reaction Reporting SystemsAntineoplastic Agents, HormonalDatabases, FactualFemaleHumansMiddle AgedParkinson Disease, SecondaryPharmacovigilanceRetrospective StudiesRisk AssessmentRisk FactorsTamoxifenWorld Health OrganizationAntineoplastic Agents, HormonalTamoxifenAdverse drug reactionDrug safetyParkinsonismPharmacovigilanceTamoxifen

Identifiers

PMID29862427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.